Vor Biopharma Inc
VOR0.151USD
-0.008-5.44%
收盤 05/09, 16:00（美東）報價延遲15分鐘
18.88M總市值
虧損本益比TTM
關於 Vor Biopharma Inc 公司
Vor Biopharma Inc. 是一家臨牀階段的細胞和基因組工程治療公司。該公司致力於將新型患者工程方法與靶向療法相結合，爲患有血液系統惡性腫瘤的患者提供解決方案。其專有平臺利用造血幹細胞 (HSC) 生物學、基因組工程和靶向療法開發方面的專業知識，對 HSC 進行基因改造，以去除癌細胞表達的表面靶標。該公司的主要工程造血幹細胞 (eHSC) 候選產品包括 tremtelectogene empogeditemcel (trem-cel)，用於治療急性髓系白血病 (AML) 和其他血癌。它旨在取代患有急性髓系白血病 (AML) 和其他血癌的患者的移植標準護理。其 VBP101 是一項 I/II 期多中心、開放標籤、首次在 AML 患者身上進行的 trem-cel 研究。
公司簡介
公司代碼VOR
公司名稱Vor Biopharma Inc
上市日期Feb 05, 2021
成立日期2015
CEODr. Robert Ang, M.D.
員工數量159
證券類型Ordinary Share
年結日Feb 05
公司地址100 Cambridgepark Drive
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02140
電話16176556580
網址https://www.vorbio.com/
公司代碼VOR
上市日期Feb 05, 2021
成立日期2015
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Tirtha Chakraborty, Ph.D.
Dr. Tirtha Chakraborty, Ph.D.
Chief Scientific Officer and Head of Technical Operations
Chief Scientific Officer and Head of Technical Operations
80.28K
-3.40%
Mr. Matthew R. Patterson
Mr. Matthew R. Patterson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
41.20K
+3.36%
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
Independent Director
Independent Director
29.43K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Han Choi, M.D.
Dr. Han Choi, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Robert Ang, M.D.
Dr. Robert Ang, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Tirtha Chakraborty, Ph.D.
Dr. Tirtha Chakraborty, Ph.D.
Chief Scientific Officer and Head of Technical Operations
Chief Scientific Officer and Head of Technical Operations
80.28K
-3.40%
Mr. Matthew R. Patterson
Mr. Matthew R. Patterson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
41.20K
+3.36%
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
Independent Director
Independent Director
29.43K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 4月18日 週五
更新時間: 4月18日 週五
持股股東
股東類型
持股股東
股東統計
佔比
RA Capital Management, LP
31.75%
Reprogrammed Interchange LLC
31.22%
5AM Ventures
5.10%
Fidelity Management & Research Company LLC
5.07%
The Vanguard Group, Inc.
1.56%
Other
25.31%
持股股東
股東統計
佔比
RA Capital Management, LP
31.75%
Reprogrammed Interchange LLC
31.22%
5AM Ventures
5.10%
Fidelity Management & Research Company LLC
5.07%
The Vanguard Group, Inc.
1.56%
Other
25.31%
股東類型
股東統計
佔比
Hedge Fund
33.29%
Corporation
31.22%
Investment Advisor
7.09%
Venture Capital
6.26%
Investment Advisor/Hedge Fund
2.57%
Individual Investor
0.70%
Research Firm
0.21%
Bank and Trust
0.01%
Other
18.65%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
171
101.61M
81.40%
+39.01M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
2023Q2
166
61.68M
92.10%
-1.24M
2023Q1
168
61.85M
93.27%
-1.28M
2022Q4
162
61.21M
94.78%
+26.97M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
39.65M
31.75%
+16.90M
+74.28%
Dec 31, 2024
Reprogrammed Interchange LLC
38.97M
31.22%
+38.97M
--
Dec 30, 2024
5AM Ventures
6.36M
5.1%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
6.33M
5.07%
-649.38K
-9.30%
Dec 31, 2024
The Vanguard Group, Inc.
1.94M
1.56%
-11.46K
-0.59%
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
1.07M
0.86%
--
--
Dec 31, 2024
Lynx1 Capital Advisors LLC
637.22K
0.51%
+637.22K
--
Dec 31, 2024
Sarissa Capital Management, L.P.
618.00K
0.49%
--
--
Dec 31, 2024
Ang (Robert M.D.)
646.69K
0.52%
+131.47K
+25.52%
Feb 06, 2025
Renaissance Technologies LLC
529.50K
0.42%
-226.51K
-29.96%
Dec 31, 2024
查看更多
持股ETF
更新時間: 5月6日 週二
更新時間: 5月6日 週二
機構名稱
佔比
Range Cancer Immunotherapy ETF
1.25%
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
Range Cancer Immunotherapy ETF
佔比1.25%
iShares Micro-Cap ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0%
ProShares Hedge Replication ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據